The seven-transmembrane receptor Smoothened (Smo) is the major component involved in signal transduction of the Hedgehog (Hh) morphogens. Smo inhibitors represent a promising alternative for the treatment of several types of cancers linked to abnormal Hh signaling. Here, on the basis of experimental data, we generated and validated a pharmacophoric model for Smo inhibitors constituted by three hydrogen bond acceptor groups and three hydrophobic regions. We used this model for the virtual screening of a library of commercially available compounds. Visual and structural criteria allowed the selection of 20 top scoring ligands, and an acylthiourea, N-(3-benzamidophenylcarbamothioyl)-3,4,5-trimethoxybenzamide (MRT-10), was identified and characterized as a Smo antagonist. The corresponding acylurea, N-(3-benzamidophenylcarbamoyl)-3,4,5-trimethoxybenzamide (MRT-14), was synthesized and shown to display, in various Hh assays, an inhibitory potency comparable to or greater than that of reference Smo antagonists cyclopamine and
Introduction
The Hedgehog (Hh) signaling pathway is involved in tissue growth and repair in the embryo and the adult. Synthesized as large precursor proteins, Hh ligands undergo autoproteolysis and lipid modifications of their biologically active aminoterminal domain. This soluble fragment mediates its action via a receptor complex containing two transmembrane proteins: Patched (Ptc) displaying a transporter-like structure and Smoothened (Smo) presumably belonging to the G protein-coupled receptor (GPCR) superfamily. The repres-sion exerted by Ptc on Smo is relieved when Hh binds Ptc, which leads to a complex signaling cascade involving the transcription factors of the Gli family and to the activation of target genes, including Ptc and Gli themselves (Ruiz i Altaba et al., 2007; Hausmann et al., 2009; Simpson et al., 2009) . Smo trafficking to the primary cilia from cytoplasmic vesicles has been proposed to be a key step for Hh transduction. Ptc is proposed to be localized to the cilia in the absence of its ligand and to inhibit signaling by excluding Smo. Thus, Smo translocation to the primary cilia upon Hh signaling might be followed by a second step leading to its activation, which has led to the proposition of a two-step mechanism of action for the activation process (Gerdes et al., 2009; Rohatgi et al., 2009; Wang et al., 2009b) . Because Smo has been exclusively associated with synaptic vesicles in mossy fiber boutons in the hippocampus (Masdeu et al., 2007) , it would be also important to determine whether this two-step mechanism of action is also observed for Smo transduction of Hh signaling in nerve brain terminal (Traiffort et al., 2010) .
Dysregulation of the Hh pathway has been associated with several types of cancers. The inactivating mutations of Ptc observed in patients with Gorlin's syndrome have been linked to a higher incidence of basal cell carcinoma (BCC), medulloblastoma, and rhabdomyosarcomas. Oncogenic mutations of Smo have also been identified in both BCC and medulloblastoma ). These tumors are considered to be independent of Hh ligands because the pathway is constitutively activated. However, several types of cancers are considered to be dependent on the overproduction of Hh ligands. This is the case for those occurring from the gastrointestinal tract, lung, colon, pancreas, breast, and prostate and for melanoma (Mahindroo et al., 2009; Scales and de Sauvage, 2009) .
Smo has been proposed as a molecular target for the action of antagonists aimed at blocking the Hh pathway and Smo inhibitors are candidate drugs for the treatment of cancers associated with dysfunction of Hh signaling. The natural and teratogenic compound cyclopamine blocks Hh signaling by directly binding Smo and slows down the growth of these tumors in various animal models (Taipale et al., 2000; Scales and de Sauvage, 2009; Simpson et al., 2009 ). When applied in vivo, cyclopamine also blocks stem cell proliferation in the mouse adult brain subventricular zone (Palma et al., 2005) . However, it was recently proposed that cyclopamine and possibly another unrelated Smo antagonist may have nonspecific effects on cell growth by acting on off-targets. They may mediate their effects on tumor growth by acting on the Hh pathway expressed in the stroma surrounding the tumor and not on the cells belonging to the tumor itself (Yauch et al., 2008; Tian et al., 2009 ). Cyclopamine has been tested for treating BCC in humans, and more potent and soluble derivatives are under development. N- ((3S,5S) 
Cur61414) has also shown efficacy for treating BCC-like lesions in a mouse model but not in humans (Williams et al., 2003; Scales and de Sauvage, 2009 ). More recent clinical trials have been conducted with a novel small molecule Smo inhibitor for treating metastatic BCC and one case of medulloblastoma Von Hoff et al., 2009) . However, in the latter, despite a rapid regression of the tumor and associated symptoms, resistance to the treatment occurred. A Smo mutation altering its ability to respond to the inhibitor was proposed to be responsible for the observed resistance . Hh blockade by a Smo antagonist has also been suggested to be a therapeutic approach to inhibit articular cartilage degeneration (Lin et al., 2009) .
Therefore, the discovery of novel molecules aimed at inhibiting Smo has therapeutic interest and should help to further characterize the potential roles of Smo both in vitro and in vivo. Molecules with diverse structural features have been identified from high-throughput screening as Hh pathway inhibitors, and several of them target Smo (Mahindroo et al., 2009; Scales and de Sauvage, 2009) . Such an approach requires intense screening efforts and is highly expensive. Virtual screening has become a major focus for the discovery of novel modulators of GPCRs. Because no three-dimensional structure of Smo has been reported so far, neither from experimental sources (i.e., NMR or X-ray crystallographic studies) nor from theoretical approaches (i.e., homology modeling and molecular dynamics simulations), we undertook a ligand-based virtual screening for new Smo antagonists. We first constructed and validated a Smo pharmacophore. Then, we applied a virtual screening procedure to select 20 compounds from the Asinex database. This approach resulted in the identification of MRT-10, a Smo antagonist displaying a unique acylthiourea scaffold. Finally, MRT-14, the corresponding acylurea derivative of MRT-10, was synthesized. In Hh cell-based assays, MRT-14 exhibited greater potency than MRT-10 comparable with that of reference Smo antagonists.
Materials and Methods
Drugs. Cyclopamine and Bodipy-cyclopamine were from Toronto Research Chemicals Inc. (North York, ON, Canada). SAG, Cur61414, and N-(4-chloro-3-(6-(dimethylamino) 
]dioxine-6-carboxamide (ZЈЈЈЈ) were synthesized as described previously (Martínez et al., 2006; Masdeu et al., 2006) . ShhN was provided by Dr. D. Baker (Biogen Idec, Boston, MA). Other compounds selected from the virtual screening were from ASINEX (Rijswijk, The Netherlands), and their structures are shown in Table 2 and Supplemental Table 2 . The structure of MRT-10 was confirmed by synthesis, and its biological activity evaluated on Hh assays was comparable with the purchased sample. Cur61414, SAG, and cyclopamine were dissolved in ethanol at a concentration of 10 mM. All other tested compounds were dissolved in DMSO at a concentration of 10 mM.
Preparation of N-(3-Benzamidophenylcarbamothioyl)-3,4,5-trimethoxybenzamide (MRT-10). A mixture of 3,4,5-trimethoxybenzoyl chloride and NH 4 SCN in acetone was heated under reflux for 30 min. benzamide was added for 1 h. The reaction was poured into crushed ice with stirring; the solid collected and crystallized in hot MeOH gave .
1 H NMR (300 MHz, CDCl 3 ) ␦ 12.69 (1 ⌯, brd s), 9.03 (1 H, brd s), 8.24 (1 H, m), 7.93-7.89 (3 H, m) 7.63-7.42 (6 H, m) , 7.10 (2 H, s), 3.96 (9 H, s).
13 C NMR (75 MHz, DMSO, d6); ␦ 179. 9, 168.3, 166.5, 153.4, 142.5, 140.4, 139.1, 135.6, 132.5, 129.6, 129.2, 128.5, 127.5, 120.3, 119.1, 116.9, 107.2, 61.1, 57.1. C 24 DMSO (d6) . The chemical shifts are given in parts per million with respect to CDCl 3 as the reference resonance. The melting points were performed on a Gallenkampf apparatus and were uncorrected.
Plasmids. The plasmids pRK5, pRK5-G 15 , and pRK5-SP-mycSmo encoding the mouse Smo sequence have been described previously (Masdeu et al., 2006) Gli-Dependent Luciferase Reporter Assay. Shh-light2 cells stably incorporating the Gli-luc reporter and the prL-TK Renilla reniformis control described in (Taipale et al., 2000) were incubated for 40 h with ShhN (5 nM) and the studied compounds. Determination of luciferase activities was carried out using the Dual-Luciferase assay according to the manufacturer's instructions (Promega, Charbonnieres-les-Bains, France). All presented data are firefly luciferase activity reported to the R. reniformis control activity. The MRT compounds did not modify significantly the R. reniformis activity at 3 M.
Alkaline Phosphatase Assay. C3H10T1/2 cells were incubated for 6 days in the presence of SAG (0.1 M) and the studied compounds. The cell-based bioassay was performed as described previously (Coulombe et al., 2004) . Bodipy-Cyclopamine Binding. The protocol was adapted from Chen et al. (2002a) . Mouse Smo-transfected cells were fixed in 4% paraformaldehyde in phosphate-buffered saline (PBS) for 10 min, washed in PBS supplemented with 0.5% fetal calf serum and incubated for 2 h at 37°C in the same medium supplemented with Bodipy-cyclopamine (5 nM) and the studied compounds. After two washes in PBS-fetal calf serum, the cells were analyzed under a DMRXA2 fluorescence microscope (Leica Microsystems, Nanterre, France) equipped with a Photometric Cool-Snap camera (Roper Scientific, Ottobrunn, Germany) using Vectashield as mounting medium and DAPI for staining of the cell nuclei (Vector Laboratories, Paris, France). Bodipy (green) and DAPI (blue) signals were analyzed in three to four representative fields per coverslip (black and white photographs with 20ϫ magnification, 1000 cells/field). Using Simple-PCI software (Hamamatsu Corporation, Massy, France), the fluorescence intensity of transfected cells determined in presence of BC (5 nM) alone or in the presence of the drugs, over the basal fluorescence measured in the absence of BC was quantified (Supplemental Table 3 ) and divided by the area occupied by the nuclei (DAPI staining) in the field. Data were expressed as percentage fluorescence intensity observed with BC alone.
Pharmacophore Determination and Virtual Screening. The chemical structures of diverse potent Hh inhibitors (Cur61414, ZЈЈЈЈ, and related molecules shown in Supplemental Fig. 1 ) were used to generate the pharmacophoric model by means of the software Catalyst (Accelerys Inc., San Diego, CA). For this purpose, HipHop (common feature hypothesis generation), which is able to generate pharmacophoric models only by identification of the common chemical features shared by the molecules and their relative alignment to the common feature set (Barnum et al., 1996) , was applied. Then, a conformational search was performed on each compound to build a representative family of conformational models to be used in turn for pharmacophore generation. Conformers were generated by application of the poling algorithm, and the best quality conformational analysis was implemented in the software Catalyst. Conformational diversity was emphasized by selection of the conformers that fell within a 20 kcal/mol range above the lowest-energy conformation. All the conformers of each compound were employed to derive a set of 10 pharmacophoric hypotheses (Supplemental Table 1 ). To enhance the probability of finding significant models, we have applied the following rules: 1) selection of the most potent molecules (Supplemental Fig. 1 ) to be included in the set, because the software pays particular attention to these molecules in the generation of the chemical feature space, and 2) maximization of the kinds (chemical groups) and relative positions (substitution pattern) of the chemical features (chemical groups) shared by the molecules, because the program recognizes the molecules as collections of chemical features, not as assemblies of atoms or bonds. The best-scored six-feature pharmacophore hypothesis was then used as a three-dimensional query to perform a database search to find structural motifs that fulfill the functional and spatial constraints imposed by the model. The Asinex Gold and Platinum Collection (http://www.asinex.com/ prod/gold.html), containing approximately 400,000 compounds, was analyzed. The structure of compounds simultaneously mapping all the pharmacophore features with a fit value of 5.00 or higher (the maximum fit allowed by a six-feature pharmacophoric model is 6.00) were retained. The resulting library, composed of 525 entries, was further pruned to 20 entries on the basis of the fit value and the uniqueness of the molecular structure (Supplemental Table 2 ); i.e., among entries belonging to the same structural class, only the best scored compound was kept. These compounds were submitted to biological tests resulting in MRT-10 as a good hit compound. From its molecular structure, two substructures were designed (Supplemental Fig. 4) . They have the ureido moiety and the central phenyl ring as common features, but differ in the presence of a terminal 6-5 heterocyclic moiety instead of a methoxyphenyl ring. They were used to perform two additional database searches.
Data Analysis. All experiments were carried out at least three times in triplicate or quadruplicate. Means and S.E.M. were calculated using Excel 2003 (Microsoft Corp., Redmond, WA). Curves were analyzed using Prism 4.03 (GraphPad Software, San Diego, CA). Data were fitted to sigmoidal dose-response curve (variable slope). The IC 50 and Hill coefficient were calculated for each experiment, and the mean Ϯ S.E.M. are reported.
Results
Drug Discovery Approach. Several inhibitors of the Hh signaling pathway identified to date bind to the GPCR Smo at the level of its heptahelical domain. These include the 660 steroidal alkaloid extracted from corn lilies called cyclopamine, which is teratogenic, Cur61414, and several synthetic compounds widely used for blocking the Hh pathway both in vitro and in vivo . Therefore, to allow the development of new Hh modulators, we have delineated a pharmacophore for Smo antagonists based on the structure of Cur61414, ZЈЈЈЈ, and several related molecules ( Fig. 1 and Supplemental Fig. 1 ) for which the structures were available (Taipale et al., 2000; Chen et al., 2002b; Williams et al., 2003; Borzillo and Lippa, 2005) . These molecules were selected for their potency as Smo antagonists and for the diversity of their chemical structures.
Owing to the lack of consistency in the reported biological data related to experimental variability in the biological responses analyzed by various laboratories, we felt it necessary to reinvestigate the antagonist properties of the lead molecules using established Hh cell-based assays under in-house homogenous conditions (Table 1, Fig. 2 ). The potency of cyclopamine, Cur61414, and ZЈЈЈЈ was determined in Shhlight2 cells, which is an NIH3T3 cell line with a Glidependent firefly luciferase reporter widely used for identifying Hh inhibitors (Taipale et al., 2000) . These cells were stimulated for 40 h with N-myristoylated Shh (ShhN) in the presence or absence of these drugs in parallel experiments. We also evaluated their ability to inhibit SAG (0.1 M)-induced differentiation of the mesenchymal pluripotent C3H10T1/2 cells into alkaline phosphatase-positive osteoblasts, a response that involves activation of Smo (Hyman et al., 2009) . ZЈЈЈЈ was found to be the most potent molecule in these assays (Table 1) .
Modeling and Virtual Library Screening. The best conformer analysis implemented in the Catalyst program was applied to each compound for collecting conformers with a range of 20 kcal/mol with respect to the global minimum that was used for building the best pharmacophoric model. This model was built up by three hydrogen bond acceptor (HBA1-3) groups and three hydrophobic (HY1-3) regions. Analysis of the superposition pattern of ZЈЈЈЈ showed a perfect fit between the inhibitor and the pharmacophoric model (Fig. 3) . For example, one of the dioxane oxygens of ZЈЈЈЈ fills HBA1 perfectly; the oxygen atoms of the carbonyl moiety match HBA2, and one of the benzimidazole nitrogen atoms corresponds to the HBA3 feature of the model. Moreover, the phenyl ring of benzodioxane is superposed to the hydrophobic region HY1, the chloro-substituent on the central aromatic ring matches HY2, and the dimethylamino group is located in the spatial region occupied by HY3. Fitting of cyclopamine and Cur61414 to the pharmacophoric model is also shown in Supplemental Fig. 2 .
Identification of the Acylthiourea MRT-10 Family of Smo Inhibitors. The Asinex Gold collection of diverse druglike molecules was screened virtually for flexible fitting to the six-feature pharmacophore model of Smo. This in silico database search identified 525 compounds. After visual inspection of this library, 20 compounds were selected for experimental testing based on the following criteria: 1) high fit score, 2) molecular weight, and 3) chemical diversity.
These compounds were purchased and analyzed for both their antagonist properties in the Shh-light2 cell luciferase assay and their ability to inhibit SAG-induced differentiation of C3H10T1/2 cells using measurement of alkaline phosphatase activity (Supplemental Table 2 ). Among the tested molecules, MRT-10 ( Fig. 1) , an acylthiourea, behaved as an antagonist with potency similar to that of the reference compound Cur61414 (Fig. 2, Table 1 ). Then, we investigated the ability of MRT-10 to modify the constitutive activity of Smo coexpressed with the ␣ subunit of the G 15 in HEK293 cells. This assay allows the analysis of the nontranscriptional activity of the Hh pathway and has been used for the characterization of the inverse agonist properties of cyclopamine and Cur61414 (Masdeu et al., 2006) . In agreement with previous results, we showed that Cur61414 displays inverse agonist properties toward this response as measured by the decreased IP accumulation that occurred in these cells 30 min after the addition of the ligand (Fig. 4) . Cur61414 inhibited the IP response (IC 50 ϭ 0.33 M) in cells expressing both Smo and G 15 to a level comparable with that observed in mock-transfected cells. ZЈЈЈЈ also displays a full inverse agonism response (IC 50 ϭ 0.12 M, Table 1 ). It is noteworthy that MRT-10 also inhibited the IP accumulation in a dosedependent manner (IC 50 ϭ 2.5 M). The inhibition of this response (70 Ϯ 5%, n ϭ 3) was partial (Fig. 4) . Thus, MRT-10 has the capacity to abrogate the constitutive activity of Smo and should be considered as an inverse agonist for this response. These data also demonstrate that MRT-10 interacts with mouse Smo. MRT-10 and the other compounds presented in Table 1 have no significant inhibitory activity on the IP production in HEK cells transfected with G 15 (Supplemental Fig. 5 ).
MRT-10 Binding to Cells Expessing Mouse Smo.
To further investigate the binding properties of MRT-10 to Smo, we analyzed whether it can compete with Bodipy-cyclopamine, which interacts with Smo at the level of its heptahelical bundle (Chen et al., 2002b) . First, we showed that Bodipycyclopamine bound to a subpopulation of HEK293 cells tran- (HY1-3) . HBA features are constituted by a smaller sphere accommodating the hydrogen bond acceptor group, by a directionality vector represented by an arrow, and by a larger sphere intended to allocate the hydrogen bond donor group of the target macromolecule. The atoms are color coded: gray, carbon; white, hydrogen; red, oxygen; and blue, nitrogen.
siently transfected for expression of mouse Smo, as determined by fluorescence microscopy and immunostaining for the Smo protein, but did not bind to cells not expressing Smo (Supplemental Fig. 3) . Then, the cells were incubated with 5 nM Bodipy-cyclopamine for 2 h in the presence or absence of various concentrations of MRT-10, cyclopamine, ZЈЈЈЈ, or Cur61414. At the end of the incubation, the cells were fixed and counterstained with DAPI. MRT-10 blocked Bodipy-cyclopamine binding to cells expressing mouse Smo in a dosedependent manner (Fig. 5) with an IC 50 ϭ 0.5 M, which was in good correlation with its IC 50 in the Shh-light2 and AP assays (Table 1) . Cyclopamine, Cur61414, and ZЈЈЈЈ abrogated Bodipy-cyclopamine binding to cells expressing mouse Smo (Table 1 ). All together, these data demonstrate that MRT-10 binds to the Smo receptor at the level of the Bodipycyclopamine binding site.
Having established that MRT-10 behaves as a Smo antagonist and thus demonstrated the validity of our pharmacophoric model, we then screened the Asinex database for additional compounds featuring the phenylthiourea moiety. Among the thirty compounds of this second focused library, we identified five additional compounds -42) ] that were able to inhibit significantly the responses at micromolar concentrations in the Shh-light2 cell and the AP assays ( Table 2 ). The observed inhibition was in the same range or lower than with MRT-10. These compounds and MRT-10 did not modify by their own the basal response in the AP assays, indicating that they do not display agonist activity (Supplemental Fig. 6 ).
Synthesis and Characterization of the Acylurea MRT-14. Because the acylthiourea moiety seems to be an important fragment for receptor recognition, we decided to synthesize the corresponding acylurea derivative MRT-14 ( Fig. 1) , which can be obtained directly from MRT-10 by an oxidative desulfuration process. It is noteworthy that MRT-14 inhibited ShhN signaling in Shh-light2 cells in a dose-dependent manner with a 4-fold increased potency compared with MRT-10 (IC 50 ϭ 0.16 versus 0.64 M) (Table 1 and Fig. 2) . The newly synthesized acylurea exhibited an inhibitory potency comparable with or greater than that of cyclopamine (0.30 M) and Cur61414 (0.14 M). A similar increase in potency for MRT-14 compared with MRT-10 was also observed in the AP assay (IC 50 ϭ 0.13 versus 0.90 M) and the IP response (IC 50 ϭ 0.6 versus 2.5 M, Table 1 ). The maximal inhibition of the IP response by MRT-14 (70 Ϯ 5%, n ϭ 3) was comparable with that observed for MRT-10, indicating that this compound is a partial inverse agonist. MRT-14 blocked Bodipy-cyclopamine binding to mouse Smo in a dose-dependent manner with an IC 50 ϭ 0.12 M. Therefore, MRT-14, like MRT-10, displays Smo antagonist properties. These data also suggest that modifications of MRT-10 structure are amenable to the design of more potent compounds. It is noteworthy that the Hill coefficients of the dose response curves of cyclopamine, Cur61414, ZЈЈЈЈ, MRT-10, and MRT-14 were not different in all assays, suggesting a similar interaction of the various molecules with the receptor, whereas analysis of the slope of the concentration-response curves in the Shh-light2 luciferase assay indicated cooperativity (n H Ϸ 2) ( Table 1) .
Pharmacophore Models of MRT-10 and MRT-14. MRT-10 and MRT-14 feature the following structural elements: an electron-rich phenyl ring (3,4,5-trimethoxy substituted) linked through an acylthiourea or an acylurea function, respectively, to a second phenyl bearing a phenyl carbamoyl residue. The superposition pattern of MRT-10 to the pharmacophore showed that one of the methoxy oxygen atoms of the ligand matches HBA1, the acylthiourea carbonyl oxygen represents HBA2, and the amide carbonyl oxygen is located within HBA3. The hydrophobic features are fitted by the aromatic rings of MRT-10 or MRT-14. The structural difference between MRT-10 and MRT-14 is also responsible for a slight different superposition to the pharmacophore (Fig. 6B) . In fact, as a consequence of the transformation of the acylthiourea into an acylurea, the anchor point of HBA2 is located between the two carbonyl groups of MRT-14, thus allowing it to make a bifurcated hydrogen bond involving the oxygen atoms of both carbonyl groups and sharing the pro- jecting point of HBA2 as a common hydrogen bond acceptor counterpart. Although MRT-10 and ZЈЈЈЈ apparently display different structures such as an additional central carbamoyl fragment present in MRT-10 with respect to ZЈЈЈЈ, the two compounds fit well with the pharmacophoric model, the six features being satisfied by different functional groups. The structures of MRT-10 and MRT-14 are relatively easy to assemble, and variations on the three aromatic core are amenable to cognate chemistry. Because we have already identified five additional antagonists displaying the acylthiourea moiety, it can be anticipated that other derivatives of MRT-10 and MRT-14 displaying Smo antagonist properties will be obtained. Indeed, exchanging the sulfur with an oxygen atom, a better hydrogen bond acceptor, from MRT-10 to MRT-14, respectively, has already led to an increase of the antagonist potency.
Discussion
Thus, this work highlights the mainstream use of virtual screening protocols based on a pharmacophore for the identification of compound leads for Smo antagonists. On the basis of a pharmacophore for Smo ligands, we have here identified and characterized the mechanism of action of MRT-10, an acylthiourea, and MRT-14, its acylurea derivative. They represent new leads that expand the chemical domain of Smo inhibitors. Although the crystal structures for the ␤1/␤2-adrenergic receptors and rhodopsin, three members of the GPCR family, have been obtained (Lodowski et al., 2009; Rosenbaum et al., 2009) , there are few data describing the identification of new compound leads for GPCRs based on homology modeling of the putative ligand binding site. This site is proposed to be located within the heptahelical bundle of these proteins, which displays some structural conservation (Schalon et al., 2008) . Homology model-based virtual screening using ligand docking and target-based scoring have encountered limited success for the identification of mGluR5 or melanin-concentrating hormone receptor modulators (Cavasotto et al., 2008; Radestock et al., 2008) . The development of a proper pharmacophore model may be limited not only by accurate pharmacological data from known reference lead molecules but also by the conformational flexibility of GPCRs that might adopt multiple conformations linked to the activation process.
In the case of Smo, this intrinsic plasticity is presumably more complex than originally thought for GPCRs. Smo is proposed to act as a dimer, to be in active and inactive forms linked to Hh signaling, and to be differentially modulated by antagonists within cytoplasmic vesicles or at the primary cilia (Zhao et al., 2007; Rohatgi et al., 2009; Scales and de Sauvage, 2009; Wang et al., 2009b; Wilson et al., 2009) . Moreover, agonists such as SAG derivatives and antagonists such as SANT-1 have been proposed to act in an allosteric manner on Smo, suggesting that multiple binding sites for Smo modulators exist at the level of the transmembrane domains (Chen et al., 2002b; Rominger et al., 2009 ). How Smo is regulated and whether Smo is modulated by an endogenous ligand remains unknown. However, allosteric ligands acting at the level of the heptahelical domain of GPCRs have been characterized recently and represent a novel therapeutic strategy (Conn et al., 2009; Wang et al., 2009a) . MRT-10 and MRT-14 block Bodipy-cyclopamine binding to mouse Smo, suggesting that both molecules are acting at the same site or at allosteric sites. Site-directed mutagenesis and molecular modeling studies have allowed the identification of allosteric binding pockets for modulators of GPCRs (Petrel et al., 2004; Simpson et al., 2010) . This approach together with binding and functional assays should help to further delineate the mechanism of action of Smo modulators.
In conclusion, we report here a successful virtual screening approach in which we identified and characterized MRT-10 and MRT-14 compounds as novel high-affinity Smo antagonists. These molecules, or more potent Smo inhibitors chemically derived from MRT-10 and MRT-14 that we are currently developing, should help to further understand Smo regulation and its interaction with accessory proteins both in vitro and in vivo. Moreover, our work has important implications for developing novel drugs for cancer therapy. (HY1-3) . HBA features are constituted by a smaller sphere accommodating the hydrogen bond acceptor group, by a directionality vector represented by an arrow, and by a larger sphere intended to allocate the hydrogen bond donor group of the target macromolecule. The atoms are color coded: gray, carbon; white, hydrogen; red, oxygen; blue, nitrogen; yellow, sulfur.
